VMD Q2 2026: A Breathing Room Moment for Viemed as Revenue Rises and Guidance Gets a Lift

Executive snapshot: the numbers that move the dial

The company reported its three- and six-month results ended June 30, 2026 from its Lafayette, Louisiana base. Net revenues for the quarter were $78.1 million, up $15.0 million year over year (roughly 23.9%), and up about 3.6% sequentially. Net income attributable to Viemed stood at $2.8 million, or $0.07 per diluted share. Adjusted EBITDA came in at $13.7 million, a 4.0% year-over-year decline partly reflecting a one-time $1.0 million gain that benefited the prior-year period through a ventilator return program that concluded in 2025.

As a reminder for the math nerds among us, the core story here isn't just the absolute magnitudes but the trajectory of cash, capital allocation, and how the business is balancing growth with capital discipline.

Operational highlights: patient bases, cash flow, and buybacks

• Cash generation and cash flow: Net cash provided by operating activities was $15.9 million for the quarter; trailing twelve months totaled $60.8 million. Free cash flow for the quarter was $8.6 million, with $34.4 million free cash flow over the trailing twelve months ended June 30, 2026.
• Share repurchases: The company repurchased and canceled 530,802 common shares for $5.1 million, at an average price of $9.65 per share, under its ongoing program.
• Ventilator and home-therapy metrics: The company ended Q2 with 12,635 ventilator patients, up 4.0% from June 30, 2025 and up 4.5% sequentially from March 31, 2026. PAP therapy patient count rose to 37,825 (up 44.0% YoY and up 5.3% sequentially from Q1), while sleep resupply patients reached 37,035 (up 46.7% YoY and 10.0% sequentially).
• Liquidity and leverage: At quarter-end, Viemed maintained a cash balance of $10.7 million and a working capital balance of $6.1 million. It repaid $2.2 million of its term loan during the quarter; long-term debt stood at $6.4 million, with $46 million available under existing credit facilities.

Updated full-year 2026 guidance: a more confident, capital-light trajectory

The company cited stronger first-half performance and favorable operating trends across ventilation and the broader platform in updating its guidance. Net revenue is now expected to be in the range of $314 million to $320 million, versus the prior range of $312 million to $320 million. Adjusted EBITDA is now expected to be $64 million to $68 million (versus $65 million to $69 million previously). Net capital expenditures are now guided to 8.5% to 10.0% of net revenue, down from 9.0% to 10.5%.

From a narrative perspective, this is a case where the company communicates acceleration in revenue discipline and a tilt toward less capital-intensive revenue streams, which should matter for both EPS delivery and cash conversion. Analysts’ EPS consensus expectations may hinge on whether the revenue trajectory translates into better operating leverage and how the non-GAAP adjustments align with ongoing dynamics in the ventilator and home-health ecosystem.

The release explicitly references a non-GAAP framework and Use of Non-GAAP Financial Information to contextualize guidance, a reminder that the apples-to-apples comparison often hinges on which charges and gains are included in reported figures versus adjusted numbers.

Implications for Viemed and sector peers

Viemed’s quarter underscores a few structural themes in home-based care and ventilation: robust revenue growth with a capital-light tilt, meaningful cash conversion, and a disciplined approach to buybacks and debt. The sequential improvement in ventilator and PAP patient counts suggests durable demand drivers, while the strong cash flow supports deleveraging and optionality around capex intensity. This sets a clean backdrop for Viemed relative to peers who are more exposed to hardware-heavy capex cycles or more aggressive debt-funded expansion plans.

For sector peers, the message is that a balanced mix of device- and service-driven revenue, coupled with prudent capital expenditure, can support both near-term upside and long-term resilience. If Viemed’s trajectory holds, look for more players to emphasize recurring-revenue components, service-based upsells, and a cautious approach to share repurchase activity when the balance sheet is leveraged or cash is constrained.

Non-GAAP framing and disclosures to watch

The press release points to the “Use of Non-GAAP Financial Information and Financial Guidance,” signaling that management believes adjusted metrics provide meaningful visibility into ongoing performance. Investors should keep an eye on how the Adjusted EBITDA series evolves as a proxy for operating efficiency, particularly as the mix shifts toward less capital-intensive revenue and recurring services.

Conclusion: steady breath, steadier path forward

Viemed’s June-quarter results present a coherent narrative: revenue momentum, improving cash generation, and a guided upgrade that nudges the floor higher while signaling confidence in growth velocity. The EPS of $0.07 on $78.1 million in revenue lands in a zone that doesn’t scream fireworks, but the secondary story—strong cash flow, a disciplined capital plan, and a revenue forecast that’s nudging upward—reads as credible progress rather than a one-off beat. For Viemed, the real test will be sustaining momentum into the second half and translating the improved net revenue outlook into tangible EPS and free cash flow expansion, even as the sector’s peers watch and recalibrate their own revenue forecast assumptions.